» Articles » PMID: 22425920

Defining Local-regional Control and Its Importance in Locally Advanced Non-small Cell Lung Carcinoma

Overview
Journal J Thorac Oncol
Publisher Elsevier
Date 2012 Mar 20
PMID 22425920
Citations 66
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Local-regional control (LRC) rates for non-small cell lung cancer after chemoradiotherapy were studied (using two different definitions of LRC) for the association between LRC and survival.

Methods: Seven legacy Radiation Therapy Ooncology Group trials of chemoradiotherapy for locally advanced non-small cell lung cancer were analyzed. Two different definitions of LRC were studied: (1) freedom from local progression (FFLP-LRC), the traditional Radiation Therapy Oncology Group methodology, in which a failure is intrathoracic tumor progression by World Health Oorganization criteria; and (2) response-mandatory (strict-LRC), in which any patient not achieving at least partial response was considered to have failure at day 0. Testing for associations between LRC and survival was performed using a Cox multivariate model that included other potential predictive factors.

Results: A total of 1390 patients were analyzed. The LRC rate at 3 years was 38% based on the FFLP-LRC definition and 14% based on the strict-LRC definition. Performance status, concurrent chemotherapy, and radiotherapy dose intensity (biologically equivalent dose) were associated with better LRC (using either definition). With the strict-LRC definition (but not FFLP-LRC), age was also important. There was a powerful association between LRC and overall survival (p, 0.0001) on univariate and multivariate analyses. Age, performance status, chemotherapy sequencing, and biologically equivalent dose were also significantly associated with survival. Histology and gender were also significant if the strict-LRC model was used.

Conclusions: LRC is associated with survival. The definition of LRC affects the results of these analyses. A consensus definition of LRC, incorporating functional imaging and/or central review, is needed, with the possibility of using LRC as a surrogate end point in future trials.

Citing Articles

Immediate start of durvalumab after chemoradiotherapy in unresectable non-small cell lung cancer UICC stage III: early results from the TORG1937/DATE study.

Grambozov B, Stana M, Zehentmayr F J Thorac Dis. 2025; 17(1):1-4.

PMID: 39975756 PMC: 11833581. DOI: 10.21037/jtd-24-1638.


Immunotherapy Improves Clinical Outcome in Kirsten Rat Sarcoma Virus-Mutated Patients with Unresectable Non-Small Cell Lung Cancer Stage III: A Subcohort Analysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR).

Ruznic E, Klebermass M, Zellinger B, Langer B, Grambozov B, Purevdorj A J Clin Med. 2025; 14(3).

PMID: 39941616 PMC: 11818499. DOI: 10.3390/jcm14030945.


Locally advanced non-small cell lung cancer: search for the optimal radiotherapy continues.

Katsurada N, Tachihara M Transl Cancer Res. 2025; 13(12):6603-6607.

PMID: 39816552 PMC: 11730452. DOI: 10.21037/tcr-24-1716.


Comparing the outcomes of MR-based versus CT-based tumor delineation in locally advanced non-small cell lung cancer treated with hypo-fractionated radiotherapy and concurrent chemotherapy.

Zhang P, Ding S, Peng K, He H, Wang D, Zhou R Transl Lung Cancer Res. 2024; 13(11):2890-2902.

PMID: 39670014 PMC: 11632429. DOI: 10.21037/tlcr-24-341.


Patterns of loco-regional progression and patient outcomes after definitive-dose radiation therapy for anaplastic thyroid cancer.

Bronk J, Augustyn A, Mohamed A, Fuller C, Garden A, Moreno A Radiother Oncol. 2024; 202():110602.

PMID: 39489425 PMC: 11720968. DOI: 10.1016/j.radonc.2024.110602.


References
1.
Perez C, Pajak T, Rubin P, Simpson J, Mohiuddin M, BRADY L . Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer. 1987; 59(11):1874-81. DOI: 10.1002/1097-0142(19870601)59:11<1874::aid-cncr2820591106>3.0.co;2-z. View

2.
Curran Jr W, Paulus R, Langer C, Komaki R, Lee J, Hauser S . Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst. 2011; 103(19):1452-60. PMC: 3186782. DOI: 10.1093/jnci/djr325. View

3.
Perez C, Bauer M, Edelstein S, Gillespie B, Birch R . Impact of tumor control on survival in carcinoma of the lung treated with irradiation. Int J Radiat Oncol Biol Phys. 1986; 12(4):539-47. DOI: 10.1016/0360-3016(86)90061-1. View

4.
Ryu J, Choi N, Fischman A, Lynch T, Mathisen D . FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer. 2002; 35(2):179-87. DOI: 10.1016/s0169-5002(01)00332-4. View

5.
Sause W, Kolesar P, Taylor S I, Johnson D, Livingston R, Komaki R . Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest. 2000; 117(2):358-64. DOI: 10.1378/chest.117.2.358. View